Evidence · Randomised trial
No neurodevelopmental benefit of cerebral oximetry in the first randomised trial (SafeBoosC II) in preterm infants during the first days of life.
- Intraventricular haemorrhage and white matter injury
- Medical
- Neurodevelopmental follow-up
- Neurology
- Preterm stabilisation
This paper is from 2019, more than five years ago. Newer evidence may have been published since.
Summary
Two-year follow-up of the SafeBoosC II phase II randomised trial in extremely preterm infants, comparing visible cerebral near-infrared spectroscopy (NIRS) monitoring with blinded monitoring during the first 72 hours of life. The trial had reduced cerebral hypoxia in the intervention group. In 115 survivors across eight European centres, neurodevelopment was assessed with the Bayley Scales and the parental Ages and Stages Questionnaire. No long-term benefit or harm on neurodevelopmental outcome was found at two years of corrected age.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.